在患有乳腺癌的老年患者中,抗体与药物结合体
Marta Bonotto1, Giulia De Pieri2, Rocco Esposto2
1Department of Oncology, Academic Hospital of Udine ASUFC, Udine, Italy.
Breast (Edinburgh, Scotland)
|February 28, 2025
概括
抗体-药物合物 (ADC) 在治疗老年患者的乳腺癌方面表现出有效性和耐受性,改善了生存结果. 需要进一步的研究来优化它们的使用,并解决老年特异性数据缺口.
科学领域:
- 在瘤学瘤学.
- 老年医学 老年医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳腺癌显著影响老年患者 (>65岁),由于虚弱,并发症和多药性,治疗具有挑战性.
- 老年人在临床试验中代表性不足,这使得乳腺癌疗法的疗效和安全性评估复杂化.
- 抗体-药物合物 (ADC) 是乳腺癌治疗的有前途的治疗类.
研究的目的:
- 审查抗体-药物合物 (ADC) 在老年人群中治疗乳腺癌的应用和结果.
- 在老年乳腺癌患者中评估特定ADC的疗效,安全性和耐受性.
- 确定需要进一步的研究和老年患者特异性的数据,以优化ADC在这个人口群体中的需求.
主要方法:
- 对临床试验数据和关于老年乳腺癌患者的ADCs的出版文献的审查.
- 对无进展生存率 (PFS) 和总生存率 (OS) 等疗效终点的分析.
- 对老年人使用ADC相关的安全性概况和不良事件的评估.
主要成果:
- 像特拉斯图祖马布埃姆坦辛 (T-DM1),特拉斯图祖马布德鲁克斯坦 (T-DXd) 和萨基图祖马布戈维特肯 (SG) 等ADC在老年乳腺癌患者中改善了PFS和OS.
- 虽然ADCs通常是可以容忍的,但可能会导致老年人不良事件的可控增加.
- 新兴的ADC显示出潜力,但需要更多的老年特异性数据.
结论:
- 在老年患者的乳腺癌治疗中,ADCs是有效和耐受的,提供了显著的生存益处.
- 适当的剂量调整对于优化ADC治疗在这个人群中至关重要.
- 专注于老年特异性数据的进一步研究对于完善老年乳腺癌患者的ADC利用至关重要.
更多相关视频
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
7.6K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.5K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Factors Affecting Protein-Drug Binding: Patient-Related Factors
34
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
34
Factors Affecting Drug Response: Overview
1.8K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.8K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
